Journal article
Human papillomavirus vaccine safety in Australia: Experience to date and issues for surveillance
MS Gold, J Buttery, P McIntyre
Sexual Health | CSIRO PUBLISHING | Published : 2010
DOI: 10.1071/SH09153
Abstract
Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8million doses of Gardasil (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conver..
View full abstractGrants
Funding Acknowledgements
MG was a member of ADRAC from 2006 to 2009 and was member of the NSW HPV expert panel. MG has made presentations at meetings on HPV vaccine safety that have been funded by CSL. JB has served on an advisory board for GlaxkoSmithKline (GSK) and serves on a data safety monitoring board for CSL. The Murdoch Children's Research Institute (MCRI) receives reimbursement from both GSK and CSL for JB's attendance at advisory board and scientific meetings. MCRI receives in kind support from Merck for HPV serology assays. PM was member of the NSW HPV expert panel and the TGA Gardasil expert panel. PM is director of the National Centre for Immunisation Research and Surveillance (NCIRS) and this centre holds funding agreements with Department of Health and Ageing and NSW Health, and the NCIRS receives in kind support from Merck for HPV serological study and from GSK for a neonatal pertussis study.